Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(1)
•••
Comment by CalgaryATEon Jun 07, 2018 2:11am
216 Views
Post# 28137476

RE:RE:RE:RE:RE:RE:RE:RE:Re: Reverse Split

RE:RE:RE:RE:RE:RE:RE:RE:Re: Reverse Split
Formatting fail... (if this also has a formatting failure I'll try it on a desktop tomorrow) The May 15 investors presentation indicated that as of May 4th there were 36 million warrants outstanding (and 18 million options). If you work backwards from the warrant expiry dates (assuming people are more likely to exercise warrants that expire sooner rather than later) we're about halfway through the December warrants. If you believe that a lot of the soon to expire 9 million June warrants are yet to be exercised, that just means that there'll be a lot less of the future December / June 2019 warrants left. For your specific question of insiders exercising warrants... They don't really have many (800k for all the insiders except Wu who has 1.3 million), about 2.1 million. They mostly have options. I get my info from: https://www.sedi.ca/sedi/SVTReportsAccessController?menukey=15.03.00&locale=en_CA - pick "Insider information by issuer" - search "Antibe Therapeutics" - view It lists what everyone has (shares, options, warrants), but it's a bit hard to see changes (whether they're buying / selling / exercising). To more easily see changes I use: https://ceo.ca/ate - there's an "insiders" link (shows no insider action since end of April)
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities